UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm

An FDA advisory committee recently recommended the return of four specific peptide drugs to the 503A Bulk Drug Substances list. This move would remove current production restrictions for compounders. The committee voted in favor of BPC-157, TB-500, KPV, and MOTs-C during a lengthy public session. These substances are widely used in fitness and wellness circles for claims regarding tissue repair and anti-inflammatory benefits.

The vote split the committee, with several members noting concerns over the lack of clinical evidence and the difficulty of defining quality standards for these substances. FDA officials, including Russell Wesdyk, highlighted that the agency currently lacks foundational data to standardize these drugs. Despite these technical hurdles, proponents argue that restricting access drives patients toward less reliable gray market suppliers rather than regulated pharmacies.

Conflict of interest concerns surfaced during the process, as some committee members maintain ties to businesses that supply these peptides. To address potential bias, the FDA added eight temporary voting members to the panel shortly before the meeting. The agency is now tasked with making a final determination. It is important to note that the FDA is not required to follow the advisory committee recommendations when finalizing their official policy.

Public testimony remained largely in favor of restoring access. Physicians and compounding industry representatives argued that patient choice and physician-led treatment options should take priority. As the debate continues, the outcome of this decision will likely influence how regulatory bodies handle synthetic peptides in the future. The FDA continues its review of three additional peptides as part of this ongoing evaluation process.